Assoc. Prof. Helmut Schaider

Academic Dermatologist

Principal Research Fellow

Projects

Drug Resistance, Melanoma Progression, Naevus surveillance

About me

Earned his MD at the Medical University of Graz, Austria in 1989. Spent one year in Berlin, Germany, at the hospitals Berlin-Buch and Berlin-Charité for internship and joined for two years as a research fellow the German Cancer Research Center (DKFZ), Heidelberg, Germany, working on tumor cell metabolism. Joined the Department of Dermatology, Medical University of Graz, Austria for residency (1994-1998). Leaving Austria to ‘The Wistar Institute’, Philadelphia, PA first as a visiting scientist, then as a postdoctoral scientist, working in Dr. Meenhard Herlyn’s lab on melanoma biology (1998-2001). After returning to Graz, Austria, attending physician at the Department of Dermatology. Habilitation (venia docendi) 2003. Assistant Professor 2003 -2103. Leading a group in melanoma biology from 2007 to 2012. Relocating to Brisbane in September 2013 to the Dermatology Research Centre (DRC) at the newly built TRI. Translational research spans melanoma prevention to therapy.

Publications

Riedl S, Rinner B, Schaider H, Lohner K, Zweytick D. Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine. BioMetals, 2014 accepted

McClenahan P, Lin LL, Tan J-M, Flewell-Smith R, Schaider H, Jagirdar K, Atkinson V, Duncan Lambie D, Prow TW, Sturm RA, Soyer HP. BRAFV600E mutation status of involuting and stable nevi in Dabrafenib therapy with or without Trametinib. JAMA Dermatology, 2014 Epub April 2014

Blake T, McClenahan P, Duffy D, Schaider H, McEniery E, Soyer HP. Distribution analyses of acquired melanocytic naevi on the trunk. Dermatology, 2014 Epub March 2014

Vinod M, Chennamsetty I, Colin S, Belloyc L, De Paoli F, Schaider H, Graier WF, Frank S, Kratky D, Staels B, Chinetti-Gbaguidi G, Kostner GM. miR-206 controls LXRα expression and promotes LXR-mediated 2 cholesterol efflux in macrophages. Biochim Biophys Acta, 2014 Epub 2014 March

Deutsch AJA, Rinner B, Wenzl K, Pichler M, Troppan K, Steinbauer E, Schwarzenbacher D, Reitter S, Feichtinger J, Tierling S, Prokesch A, Scheideler M, Krogsdam A, Thallinger GG, Schaider H, Beham-Schmid C, Peter Neumeister P. NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer specific survival in patients withaggressive B-cell lymphomas. Blood, 2014 Epub February 19, 2014

TGF-beta1 and TNF-alpha differentially regulate Twist1 mediated resistance towards BRAF/MEK inhibition in melanoma. Menon DR, Wels C, Bonyadi Rad E, Joshi S, Knausz H, Lade-Keller J, Brandner JM, Schaider H. Pigment Cell Melanoma Res. 2013 Nov; 26:912–916.

Transcriptional activation of ZEB1 by Slug leads to cooperative regulation of the EMT like phenotype in melanoma. Wels C, Joshi S, Koefinger P, Bergler H, Schaider H. J Invest Dermatol. 2011 Sep;131(9):1877-1885.

The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators. Koefinger P, Wels C, Joshi S, Damm S, Steinbauer E, Beham-Schmid C, Frank S, Bergler H, Schaider H. Pigment Cell & melanoma Res. 2011 Apr: 24(2):382-385.

HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta. Damm S, Koefinger P, Stefan M, Wels C, Mehes G, Richtig E, Kerl H, Otte M, Schaider H. J Invest Dermatol. 2010 Jul;130(7):1893-1903.

 

Research fields

Melanoma and non-melanoma skin cancer